Neglected diseases by Rawlins MD
Evidence from animals and humans now provides
confirmation that behavioural changes may be seen
even at low doses of alcohol consumption.
Ikonomidou et al report that exposure of the rat
brain to ethanol for a period of hours during a specific
developmental stage induces an apoptotic neurode-
generative reaction that deletes large neurones from
several developing sites.7 Charness et al report that cell
adhesion molecules are inhibited even at exposure to
low concentrations of ethanol. These have subsequent
effects on neuronal migration, fasciculation, and
synaptogenesis, all vital to the developing brain.8
Sood et al report a prospective study of 501 mother-
child dyads in which the child’s behaviour was adversely
affected even at low levels of alcohol consumption—as
low as one drink per week. They further report that a
dose-response relation existed between the level of alco-
hol consumed and behaviours seen. Children exposed
to any level of alcohol, compared with those not
exposed, showed 3.2 times greater odds of delinquent
behaviour. These relations continued even after other
factors were controlled for.9 Knupfer et al argue that
because of methodological problems, such as differing
classifications of drinking practice and the imprecise
definition of what low level consumption meant in early
studies, more research is needed before conclusive
evidence is available about the dose-response relation.10
Evidence is currently emerging, but is as yet incon-
clusive, about the exact dose of alcohol that is safe in
pregnancy. The likelihood is that individual differences
in alcohol metabolism may protect most women when
drinking small quantities. Currently we cannot predict
who is and is not at risk.
A small unpublished study carried out by one of
the authors (MAS) at St George’s Hospital in London
showed that just under 50% of those attending the
teenage antenatal clinic drank more than four units on
a single occasion and 27% occasionally got drunk. A
further 25% drank at least once a week. Kaskutas and
Graves studied alcohol consumption in 321 pregnant
women. They found that when self selecting drinks, the
size of the drinks was up to 307% greater than standard
measures. The authors concluded that risk based on
current assumptions might actually be much higher
than previously expected.11
Unlike the position of the department of
health—that one to two units a week in pregnancy are
safe—the position adopted increasingly in other coun-
tries is that no level of alcohol consumption is known
to be safe in pregnancy. A health promotion message
about a safe amount of alcohol, although designed to
protect the pregnant mother and the developing child,
can be dangerous as it can be so easily misinterpreted.
The uncertain level of individual risk to the developing
fetus together with the possibility of misinterpreting a
health promotion message mean that the only safe
message in pregnancy is abstinence from alcohol.
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Neglected diseases
“Priority medicines for Europe and the world” is a wake up call from WHO
Few readers of the BMJ were probably aware oreven cared that the presidency of the EU Councilwas held by the Dutch government during the
second six months of 2004.Nevertheless, history is likely
to remember the Dutch presidency with gratitude. For in
the run up to it, the Dutch government commissioned
the World Health Organization to develop a research
agenda for the European Union that was based on pub-
lic health needs for priority medicines.
The commendable report was published last
November.1 Masterminded by Warren Kaplan and
Richard Laing, and using a new approach, it is a work
of scholarship. It covers a wide range of critical issues
and makes many far reaching research proposals for
the European Union. But underlying these extensive
data and careful analyses are some chilling implica-
tions. Here are a few.
Firstly, contemporary notions of neglected diseases
are far too circumscribed. They include both rare
(orphan) diseases as well as common disorders (mainly
communicable) of developing countries. But the
neglected diseases also include a range of other condi-
tions that are major burdens in all countries and for
which we have few or no effective remedies. Epidemic
influenza, appearing annually, probably causes a
million deaths a year worldwide. But pandemic
influenza, appearing every few decades, has much
more devastating consequences. The pandemic of
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1918-9, for example, killed an estimated 40-50 million
people. Research into influenza, in relation to its cata-
strophic potential, is underfunded.2 Worse still, we do
not even seem able to provide sufficient vaccine to
control epidemic influenza in the most developed
countries. Little confidence exists that we could under-
take a global immunisation programme for an
influenza pandemic even if we had sufficient warning
of its antigenic profile unless we can sharpen up on
manufacture and distribution. Other notable examples
of neglected diseases afflicting the world include
antibacterial drug resistance, chronic obstructive
pulmonary disease, alcoholic liver disease, and stroke.1
Secondly, the pharmaceutical industry is clearly
unable to meet the needs of people with neglected
diseases. This is not a criticism but a fact, for the
pharmaceutical industry is a business and needs to pro-
vide its shareholders with a return on their investment.
Many neglected diseases are unlikely to to do this and
investment represents a great commercial risk. The
industry will continue to play a major part in the discov-
ery and development of drugs; but we need much
greater pluralism in both the funding and discovery of
novel treatments.
Examples of this pluralistic approach already exist.
Substantial public funds for basic and clinical research,
ultimately aimed at producing new forms of treatment,
are available in the United States and to a lesser extent in
Europe. The research agenda in theWHO report should
be a major feature of the European Union’s next
research programme. For this we must rely on the influ-
ence of the Dutch presidency. But Europe also needs to
harness the potential of public-private partnerships
along the lines of the Global Alliance for TB Drug Devel-
opment, or the Hereditary Disease Foundation in the
United States.3 Public-private partnerships involve joint
investment of resources by bodies including universities,
government supported research organisations, pharma-
ceutical companies, venture capitalists, and research
based charities. The Hereditary Disease Foundation’s
public-private partnerships include, for example, not
only the foundation itself but several pharmaceutical
companies and academic researchers of the Huntington
Study Group collectively seeking an effective treatment
for Huntington’s disease; and that of the Global Alliance
for TBDrug Development is a joint initiative between the
Rockefeller Foundation, the Bill and Melinda Gates
Foundation,WHO, a group of university based investiga-
tors, and several private companies.3
Thirdly, the cost of developing a new drug must be
reduced.4 Unless savage cuts can be made in the
current cost of bringing a new drug to the
market—over $800m (£423m; €605m) and rising at the
rate of 10% a year5—drug development will come to a
standstill. Half this sum seems to be consumed by clini-
cal development programmes. But real inroads need to
be made into reducing all regulatory requirements if
affordable new drugs are to be available to consumers.4
Promisingly, the problem has been acknowledged by
both the US Food and Drug Administration and the
European Medicines Agency,6 7 but international
action is needed if these difficulties are to be resolved.
Radical regulatory reform that is acceptable to the
United States, the European Union, and Japan will be
essential to relieve our current woes. This will have to
include reducing the burdens of preclinical studies and
adopting innovative approaches to investigating
efficacy and safety in patients.4
Finally, the boundaries between primary and
secondary prevention of disease clearly need to be
redrawn. The silos currently occupied on the one hand
by public health specialists and on the other by
clinicians must be eroded. Prevention and control of
disease need to go hand in hand. The transfer of the
public health functions of the Health Development
Agency to the National Institute for Clinical Excellence
(NICE) as of April 2005 offers a real opportunity for
this to happen—at least in England.8
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The treatment of lupus nephritis
New and more conservative approaches in treatment are a major advance
For 30 years the US National Institutes of Healthhave dominated the treatment of lupus nephritiswith controlled trials of monthly high dose intra-
venous pulse cyclophosphamide, now the standard
treatment for nephritis and severe lupus. However,
adverse effects such as ovarian failure and infections are
significant with prolonged treatment.1 As most lupus
patients are women of childbearing age, this price has
been high and patients and clinicians are questioning
this protocol. Recent studies offer two different
approaches that may be as effective and better tolerated.
Additional references w1-w4 are on bmj.com
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